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ABSTRACT 
 
 
 
Stem cell research is a controversial topic that strongly affects society, but 
misinformation to the public complicates the issue.  This IQP clarifies the types and 
sources of stem cells, discusses their applications, and outlines the religious and political 
opposition that make support for the research difficult.  We hope the public will read this 
report open mindedly to formulate their own educated opinion on this complex topic. 
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EXECUTIVE SUMMARY 
 
Due to misinformation released to the public on the topic of stem cells, many 
people believe the use of stem cells, no matter what their source of origin, was a bad idea.  
However, as more information is released on the subject, and as people are becoming 
aware of what already has been done with stem cells, many people are beginning to 
rethink their view on the current controversial research.  Despite all the reported benefits, 
many people are still against using stem cells, including some major religions, which 
makes it all the more important to “shed light” on the subject of stem cells. 
Stem cells are the starting cell type for every cell in the body.  When developing 
in the womb, every cell started out as a stem cell and then developed into a specific cell 
type such as lung, heart, or tissue cell.  Depending on the type of stem cell, some posses 
the ability to differentiate into one or many cell types, some stem cells can even develop 
into any cell type.  Due to this ability (pluripotency), these cells are a very hot topic in 
regenerative therapies for all sorts of diseases such as Alzheimer’s, Parkinson’s, heart 
disease and many others (Frequently, 2004). 
All stem cells can be classified under four different categories that describe their 
potency, or, the extent into which they can differentiate.  These four categories are 
totipotent, pluripotent, multipotent, and unipotent.  A totipotent stem cell can give rise to 
all the cell types in the body including the entire embryo and placenta; a fertilized egg 
cell is the only cell that is considered totipotent.  A pluripotent stem cell is derived from a 
totipotent stem cell and can make up any type of cell in the body, except those types of 
cells used to make embryonic tissue (such as the egg).  Embryonic stem (ES) cells are an 
example of this type.  A multipotent stem cell is derived from a pluripotent stem cell, 
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they can develop into many related cell types found in the body but they cannot develop 
into all types.  Finally, a unipotent stem cell can only develop into one type of stem cell, 
usually the same tissue it was extracted from.  These types of cells are focused on one 
job.  They develop into their specified and final cell type.  The latter two types are often 
referred to as “adult stem cells” which will also be discussed.   
Stem cells can also be classified by their source.  There are two different types of 
stem cells based on source. The first and least controversial are adult stem cells.  These 
stem cell types can be found in the brain, blood, cornea, retina, heart, intestines and 
several other areas (Weiss, 2005).  The problem with all adult stem cells is that they are 
limited in their medical usage.  They have already transformed into a specific type of cell, 
and are only found in one or very few areas, and thus could not be used to create any type 
of cell (Frequently, 2004).  However, embryonic stem (ES) cells do not have this 
disadvantage.  ES cells are pluripotent and therefore have the ability to become any cell 
type, making ES cells a primary target for medical research.  The embryonic stem cell’s 
ability to develop into almost any type of cell is the primary reason why it is of great 
interest to scientists.  Scientists hope to be able to make cell lines of all types, including: 
bone marrow, nerve cells, heart muscle, organ tissue, and many other types in the hope of 
curing diseases and increasing life expectancy.   
Stem cell research shows great promise in both the adult and embryonic fields.  
Both areas have medical treatments currently in or on the verge of clinical trials, and they 
both have great results from animal testing in the labs.  Despite the advances and promise 
of treatments, annual investments have dropped over the past couple years (Glaser, 
2004).  This is probably due to the constant debate over the ethical and moral status of ES 
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cells, and the current U.S. legislation blocking the derivation of new ES cell lines.  
Unfortunately, sometimes all stem cell research gets incorrectly pulled into the debate of 
whether embryos should be destroyed for research, when this topic only pertains to ES 
cell research and not adult stem cells.  It is imperative to remember that adult stem cell 
research and therapies use the person’s own stem cells for treatment and do not involve 
any “killing” of embryos.  With stem cell research being on the cusp of making life 
saving discoveries, it is even more important now than ever to try to understand all sides 
of the ethical and moral debate. 
Various religions around the world also have mixed opinions about the use of 
stem cells in medical research.  Some like the Catholic Church are very strict and are 
against all embryonic stem cell research.  However religions like Judaism are for any 
medical advances that benefit the human race, so long as certain moral and ethical 
barriers are not crossed, and therefore are proponents of stem cell research. However, 
besides the obvious division of opinion about using embryonic stem cells between 
religions, there is also a debate between the members of the same religion.  As Dr. 
Cheshire explains, “...how society decides to treat the least of human lives is a measure of 
how it chooses to value vulnerable and impaired human beings in general” (Cloning, 
2006).  As such, governments of countries capable of stem cell research are attempting to 
take political measures in the best interest of their country. 
The United States currently allows federal funding only on ES cell lines derived 
before August 2001, but allows the private sector and individual state funding much more 
freedom (Weiss, 2005).  The U.S. has struggled with the ethical stand point of funding 
human embryo work ever “since the advent of in vitro fertilization, which produced the 
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first ‘test-tube’ baby in 1978” (Dunn, 2005).  The United States began making political 
and legal distinctions about stem cells in 1997 with the Dickey Amendment.  This 
amendment was introduced by Representative Jay Dickey, and made it illegal to use 
federal funds for embryonic research (Johnson and Williams, 2006).  One of the major 
political hurdles with stem cell research is whether the government should pay for it even 
though there are citizens of the country who may believe it unethical and do not want 
their tax dollars used for it.  This was the reason for the Dickey Amendment.  In addition 
to this, on August 9, 2001, Bush went and undid everything that President Clinton had 
done to expand and encourage embryonic stem cell research when he “announced that 
federal funding would now be restricted to a limited number of stem cell lines already 
created by that date” (Dunn, 2005).   
Luckily state laws are able to sidestep both Bush’s regulations and the Dickey 
Amendment, and help fund ES research with their own money.  California has especially 
taken a strong leading role with its state bond funding of an International Stem Cell 
Institute.  Hopefully with more states supporting the research and a new election year 
approaching, expansion of funding will help keep the United States at the forefront of the 
research.  Senator Edward M. Kennedy said it best: “There are some issues you just can’t 
get off the national agenda, and this is one…Stem cell research is going to happen.  It 
will happen quicker with the President’s support, but all of us who are supporting this 
important research know that it is inevitable.  It’s just a question of when” (Klein, 2006). 
Stem cell research has advanced tremendously in the past few years, however 
religious and political opposition, in addition to ongoing scientific difficulties, make stem 
cells a very difficult field to work in.  However, with continued support from private 
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companies and hopefully more support from state governments that have the technology 
to work with them, stem cell research will be able to make many more break-throughs 
and potentially help many patients around the world. 
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PROJECT OBJECTIVES 
 
 
 The objectives for this IQP are to explain why the topic of stem cells is a topic 
relative to society, to help prevent misinformation, and to help educate the public about 
its importance.  To help better understand this topic we have divided this IQP into 
chapters to discuss issues such as the different types and sources of stem cells, their 
applications, moral and ethical issues, and political issues.  The issue of stem cells is very 
current, and will continue to be an essential topic of discussion as more advances are 
made. 
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CHAPTER-1:  STEM CELL TYPES AND SOURCES 
 
 
The controversial topic of stem cells is a relatively new one.  Scientists at the 
University of Wisconsin in Madison in November of 1998 reported that they had 
succeeded in removing cells from embryos donated from fertility clinics and had 
generated the first human embryonic stem cell line (Weiss, 2005).  James Thomson and 
his team of scientists expected this feat of scientific ingenuity to be met with applause 
and admiration; instead the discovery was overwhelmed with controversy and debate.  
Many religious groups claimed the embryos that the young stem cells were obtained from 
are full fledged human beings, and as such are a member of society and should have all 
the rights to a free life as any other human being on earth.  Some even went as far as to 
call it “cannibalism” (Weiss, 2005).   
Due to misinformation released to the public on this new scientific endeavor, 
many people started believing that the use of stem cells, no matter what their point of 
origin, was a bad idea.  However, as more information is released on the subject, and as 
people are becoming aware of what already has been done with stem cells, many people 
are beginning to rethink their view on the current controversial research.  Despite all the 
reported benefits, many people are still against it including some major religions, which 
makes it all the more important to “shed light” on the subject of stem cells. 
Stem cells are the starting cell type for every cell in the body.  When developing 
in the womb, every cell started out as a stem cell and then developed into a specific cell 
type such as lung, heart, or tissue cell.  Yet during this differentiation process, stem cells 
also retain the ability to make copies of themselves in an undifferentiated state.  Thus 
they are considered “immortal” for the life of the organism, and can even be grown in 
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culture indefinitely.  Depending on the type of stem cell, some posses the ability to 
differentiate into one or many cell types, some stem cells can even develop into any cell 
type.  Due to this ability (pluripotency), they are a very hot topic in regenerative therapies 
for all sorts of diseases such as Alzheimer’s, Parkinson’s, heart disease and many others 
(Frequently, 2004).   
 
Stem Cell Classification by Potency 
All stem cells can be classified under four different categories that describe their 
potency, or, the extent into which they can differentiate.  These four categories are 
totipotent, pluripotent, multipotent, and unipotent.  A totipotent stem cell can give rise to 
all the cell types in the body including the entire embryo and placenta; a fertilized egg 
cell is the only cell that is considered totipotent.  A pluripotent stem cell is derived from a 
totipotent stem cell and can make up any type of cell in the body, except those types of 
cells used to make embryonic tissue (such as the egg).  An example of pluripotent stem 
cells are embryonic stem (ES) cells (Figure-1), one of the main focuses of this report 
(Frequently, 2004).   
 
 
 
 
 
Figure-1: Human Embryonic Stem Cell (Marchant 2006) 
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A multipotent stem cell is derived from a pluripotent stem cell, they can develop into 
many related cell types found in the body but they cannot develop into all types.  A good 
example in this category is hematopoietic stem cells (HSCs) that can form all the cellular 
components of blood.  These types of stem cells are often referred to as “adult stem cells” 
which will also be discussed.  Finally, a unipotent stem cell can only develop into one 
type of stem cell, usually the same tissue it was extracted from.  These types of cells are 
focused on one job.  They develop into their specified and final cell type.  For instance, 
an epithelial stem cell can form skin cells.  It then remains a skin cell for its lifetime 
(Frequently, 2004). 
 
Stem Cell Classification by Source 
 
Stem cells can also be classified by their source.  There are two different types of 
stem cells based on source. The first and least controversial are adult stem cells, one of 
the most common being hematopoietic stem cells.  Hematopoietic stem cells (Frequently, 
2004) are the precursors of mature red and white blood cells that have the ability to 
replace bone morrow upon its destruction as well as produce mature blood cells.  Other 
adult stem cell types can be found in the brain, blood, cornea, retina, heart, intestines and 
several other areas (Weiss 2005).  Some advance has already been made in this field, 
such as the ability to perform adult stem cell replacement, through bone marrow 
transplantation, as a treatment for blood cancers and other blood disorders (Frequently, 
2004).  Another advance in this field has been the usage of umbilical cords, which 
contain many HSCs in them.  These stem cells have the advantage of being much 
“younger” than bone marrow-derived HSCs, and therefore are less likely to be rejected 
by the patient.  Thus far, umbilical cord blood stem cells have been used for stem cell 
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transplantation to reconstitute blood cell formation in patients that have been exposed to 
radiation, or given drugs for cancer or leukemia. Also, in some genetic diseases, a 
transplantation of umbilical cord blood cells can give them a new system that can form 
healthy blood cells (Frequently, 2004).  These therapies will be described in more detail 
in Chapter 2. 
Other types of stem cells found in bone marrow include endothelial stem cells and 
mesenchymal stem cells. Endothelial stem cells form the vascular system. Most, if not 
all, epithelial tissues contain stem cells. They are the primary mechanism for normal 
tissue renewal and for regeneration following damage (Slack, 2000).  Mesenchymal stem 
cells form bone, muscle, fat, and cartilage (Glossary, 2004).  Mesenchymal stem cells are 
also involved with repair in bone and cartilage.  Once these cells divide, their progeny 
become committed to one function that is characteristic of a specific tissue type (e.g. 
cartilage) (Caplan, 1991). 
Another type of adult stem cell is the neural stem cell; these can grow from adult 
brain tissue in culture media (Frequently, 2004) (Figure 2).  Neural stem cells not only 
exist in a developing mammal, but they have also been found in the central nervous 
system of all developed mammalian organisms, including human beings (Gage, 2000).  
“The term ‘neural stem cell’ is used loosely to describe cells that (i) can generate neural 
tissue or are derived from the nervous system, (ii) have some capacity for self-renewal, 
and (iii) can give rise to cells other than themselves through asymmetric cell division” 
(Gage, 2000).  Research by Clas Johansson has shown that new neurons are being 
continuously generated in specific areas of the adult nervous system.  These neurons have 
been shown to be created by multipotent stem cells (Johansson et al, 1999).  Some 
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research involving rats that had spinal cord injuries were shown to have increased 
ependymal cell proliferation.  Ependymal cells give rise to cells that proliferate rapidly, 
they also generate neurons.  This data lead the researchers to believe that these 
ependymal cells were in fact neural stem cells and are involved in the process of 
repairing central nervous system injuries (Johansson et al, 1999). 
 
Figure-2: Possible Neural Stem Cells (Gage, 2000) 
 
 
In the adult brain, the generation of new neurons, neurogenesis, occurs in just two 
regions (Bjorklund and Lindvall, 2000).  These findings suggest the possibility that the 
brain has a latent capacity for self repair, however it is severely limited (Bjorklund and 
Lindvall, 2000).  What is believed to perform these repairs is a type of neuronal stem cell.  
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This stem cell located in the central nervous system is limited in its mobility and 
accessibility, however it has been found to initiate and perform repairs (Johansson et al, 
1999).  If we were able to isolate and maintain a cell line of these neuronal stem cells, 
many degenerative brain diseases could be stopped and perhaps reversed.  For example, 
the neurons required to treat Parkinson's disease can be obtained from the fetal brain 
(McKay 2000).   
“James Thomson and Thomas Okarma suggested that human ES cells will someday 
provide a potentially unlimited source of cells, differentiated in vitro, for transplantation 
therapies involving the liver, nervous system, and pancreas. Irving Weissman alluded to 
the possible use of ESCs to enhance the success of whole-organ transplantation. If HSCs 
derived from human ESCs could be successfully transplanted into the blood system of a 
transplant recipient (by using immunosuppressive drugs), any further implant tissue (say 
kidney or pancreas) developed with the same ESCs would not, in theory, be rejected by 
the recipient because the immune cells produced in the recipient’s blood by the HSCs 
would see the implant tissue as ‘self’” (Stem Cells, 2002). 
 
Another example of adult stem cells are renal stem cells (stem cells from the 
kidney).  These are an exciting topic for those working on adult stem cells due to their 
potential for treating a variety of kidney disorders; however, we are still not completely 
sure if they exist (Watorek and Klinger, 2006).  There is however significant amounts of 
data that points to their existence and their possible use in kidney failure, renal diseases 
and cancer of the kidney (Watorek and Klinger, 2006).  To determine if renal stem cells 
could generate the cell types found in the kidney, researchers examined the 
“differentiation potential of metanephric mesenchymal cells isolated on the first day of 
kidney development” (Oliver et al, 2002).  The cells were examined and found to be 
“kidney-specific mesenchymal cells” (Oliver et al, 2002).  They also found that the cells 
could indeed differentiate into the specific cell lines found in the kidney, suggesting that 
these stem cells were specific to the kidney organ (Oliver et al, 2002). 
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Research in the field of adult stem cells has given us much insight into what could 
be done with these cell lines, such as controlling and protecting vital organs from 
inflammatory and destructive autoimmune reactions (van Laar and Tyndall, 2006), 
treatment of cancers (Weiss, 2005), and their possible use in the treatment of several 
other debilitating disorders (Figure-3).   
  
Figure-3: What are adult stem cells (Weiss, 2005) 
 
The problem with all adult stem cells is that they are limited in their usage.  They 
have already transformed into a specific type of cell, and are only found in one or very 
few areas and thus could not be used to create any type of cell (Frequently, 2004).  
However, embryonic stem (ES) cells do not have this disadvantage.  ES cells are 
pluripotent and therefore have the ability to become any cell type, making ES cells a 
primary target for medical research. 
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ES cells, in some ways, are different from adult stem cells.  Their origin is 
different and their potential use in medicine is much greater.  The embryonic stem cell’s 
ability to develop into almost any type of cell is the primary reason why it is of great 
interest to scientists.  Scientists hope to be able to make cell lines of all types, including: 
bone marrow, nerve cells, heart muscle, organ tissue, and many other types in the hope of 
curing diseases and increasing life expectancy (Figures-4 and 5). 
  
    Figure-4: Stem Cell Potential (SoRelle, 2004).           Figure-5: Ideal progression of stem cell therapy                           
       (Odorico et al., 2001). 
 
The problem with ES cells lies with having to terminate a potential human life in order to 
obtain the cells.  Most ES cells are extracted from embryos created by in vitro 
fertilization (IVF); in vitro fertilization is the “fertilization of an egg in a laboratory dish 
or test tube” (In Vitro Fertilization, 2006).  After the zygote is created, it progresses 
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through several cell divisions until it becomes a blastocyst which takes five days (Figure-
6). 
 
Figure-6: Development of a Blastocyst (The Amazing Beauty, 2006). 
 
 
At 5 days, the embryo consists of an inner cell mass (ES cells) and the outer cell mass.  
Extracting the inner cell mass from the embryo destroys it.  Usually during IVF 
procedures, excess embryos are created.  If they are not used by the parents, with their 
signed consent they can be donated for research purposes (Weiss, 2005).  Many scientists 
see the possibility for the usage of ES cell lines in regenerative treatments for organ 
transplants. 
Stem cell research isn’t all hype however.  Scientists are making progress in the 
field of embryonic stem cell research.  Typically the process of producing a stem cell line 
looks like the following (Figure-7). 
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Figure-7: Stem Cell Line Production (Odorico et al, 2001). 
 
 
The isolated inner cell mass cells are plated on a feeder layer (typically irradiated mouse 
fibroblast cells) that provides growth factors to feed the ES cells.  More recently, 
protocols have been developed for growing ES cells on human feeder lines to prevent 
contamination of animal (mouse) proteins with the human lines.  Once the ES cell 
cultures are established research can commence.  The cells in this state are still 
undifferentiated, meaning that they are still capable of becoming any cell type in the 
human body.  Scientists are still unsure about how to force the ES cells into becoming 
certain types of target cells (i.e. heart muscle), however that is one of the primary 
research areas (Odorico et al, 2001). 
Unfortunately there is a lot of resistance to ES research.  Most of it ethical, either 
from personal moral views or from religious stand points.  Many people see the donating 
of these embryos to science as terminating a possible human life.  However, is this 
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embryo which is smaller than the period at the end of this sentence and which contains no 
heart beat, no nervous system, no brain, a life?  Advocates of stem cell research point out 
that IVF clinics worldwide are “bulging with thousands of unwanted embryos” that 
would be slated for disposal via autoclaving (Weiss 2005).  So if the cells are going to be 
destroyed anyway, why not use them for science that could help save lives? This topic 
will be discussed in more detail in Chapter 3.   
 
Parthenotes 
Part of the resistance to stem cell research is due to misunderstanding.  Despite all 
the facts released to the public, misconceptions are still very frequent.  One of the largest 
misconceptions is that all stem cell research destroys embryos.  This is untrue, only ES 
cell research destroys embryos.  Luckily, there is an ethical solution to this exact problem 
that has already been experimented with.  “Using chemicals that mimic a sperm's arrival, 
scientists in recent years have triggered parthenogenesis…” (Weiss 2001).  
Parthenogenesis is the process in which an egg develops into an embryo without the 
fertilization of the sperm (Cibelli et al, 2002).   ES cell lines have been established from 
monkey parthenote embryos (Cibelli et al, 2002) and murine parthenote embryos.  
Although human parthenote embryos were created in 2001 (Cibelli et al, 2001) ES cell 
lines were not established at that time.  Very recently, human ES cell lines have been 
created by Tiziana Brevini and Fulvio Gandolfi at the University of Milan.  They used 
104 eggs donated by women at fertility clinics (Marchant, 2006).  Brevini and Gandolfi 
were able to create two separate ES cell lines, which is a huge step forward in human 
parthenotes and stem cell research.    
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In the monkey parthenote research by Jose Cibelli, four out of 28 eggs (14%) 
developed to the blastocyst stage which is the necessary stage to retrieve the stem cells.  
The stem cells were removed from the inner cell mass and plated.  After 1 week cell 
proliferation was noted in three of the inner cell mass cell lines, and a stable cell lines 
called “Cyno-1” was developed.  Although only 14% of the eggs developed long enough 
to reach the desired stage of development, the possibility of using parthenotes in 
exchange for embryonic stem cells was shown to be viable (Cibelli et al, 2002).   
These parthenotes always die before they can be implanted in the womb, but live 
long enough to be able to extract the inner cell mass which contains the embryonic stem 
cells.  “Those cells [stem cells obtained from the parthenotes] turned into intestine, 
skeletal muscle, retina, hair follicles, cartilage, bone and other cell types -- even heart 
cells beating in unison. Some turned into nerve cells that secreted the brain chemical 
dopamine, the kind of cell that is gradually lost by Parkinson's patients.  The idea … is to 
grow replacement cells and tissues from a female patient's own eggs so they are 
genetically so similar to the woman that they won't be rejected by her immune system” 
(Weiss 2001).  Since the parthenotes can not live long enough to be born there are fewer 
ethical concerns because it can never become a human being (Marchant, 2006).  Human 
eggs are still destroyed in the process however.  So perhaps parthenote embryos can serve 
as an alternative source for ES cells until we can develop other procedures. 
 Despite the advances and prospect of the research, many people still object to 
parthenote research, some even more so than embryonic stem cells.  "The same people 
who were up in arms about doing research on embryos were up in arms about research on 
Parthenotes … They correlated this with virgin birth. They correlated it with Christ" 
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(Weiss 2001).  Since the word parthenogenesis is translated to “virgin birth” from Greek, 
many Christian religions are even more upset about parthenote research than stem cell 
research because they see a parthenote as being born virgin, just like Christ. 
Despite the political, moral and scientific battles that are being waged over the 
issue of stem cells, research is continuing and progress is being made.  We have already 
talked about many instances in which stem cells save lives or show great signs of 
promise.  Results like these will be discussed in Chapter-2, and continue to produce 
optimism for the advocates of stem cell research.  The hope that stem cells will save 
many more lives may soon be realized. 
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CHAPTER-2:  STEM CELL APPLICATIONS 
 
 
Stem cell research has opened the door to an entirely new realm of medical 
research.  Although we have only begun to understand the mechanism in which stem 
cells work, much progress has been made in the field.    However, as we learned in 
Chapter 1, not all stem cells are alike and therefore each stem cell type has a different 
potential for research.  It is important to distinguish between those types to get a better 
understanding of what is in the distant future.  In addition, much misinformation has been 
published on stem cell successes, making it difficult to distinguish fact from hype.  In this 
chapter, exploring what has been done, what can be done, and perhaps most importantly 
distinguishing fact from fiction will allow everyone to understand more about stem cell 
research and allow the general public to obtain a clearer and more objective view on this 
topic. 
 
Adult HSC Treatments 
 One of the largest misconceptions is that stem cells have not saved a single life.  
This is untrue; people forget that bone marrow and umbilical cord blood transplantations 
have been saving lives for decades (Verfaillie, 2002).  More than 70 diseases and 
disabilities are treatable with adult hematopoietic stem cells (HSCs) (discussed in chapter 
1), such as breast cancer, leukemia, and sickle cell anemia (Earll, 2005).  Stories from 
patients receiving these HSC treatments have given hope to researchers searching more 
ways to use stem cells in medical research.  For instance, 16 year-old Nathan Salley is 
alive today because of stem cells transplanted from an umbilical cord.   Nathan suffered 
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from Acute Myloid Leukemia, an often fatal childhood form of Leukemia (Earll, 2005); 
such blood-based diseases are the type HSC treatments are best designed to treat.   
 Many other lives have been improved through adult HSC stem cells.  “Thirty-six-
year old Susan Stross is one of more than 20 MS patients whose conditions have 
remained steady or improved after receiving an adult HSC stem cell transplant. The same 
results are reported with several hundred patients worldwide” (High, 2001). 
 
Umbilical Cord Blood HSCs 
Umbilical cord blood is an excellent source of HSCs, no anesthesia has to be 
delivered as with bone marrow-derived HSCs, and the cells are less likely to be rejected 
by the patient (Viacell, 2006).  Obtaining bone marrow includes putting the donor under 
anesthesia, injecting a syringe in a bone (typically the hip) and removing some of the 
bone marrow cells.  The cells are then injected into the patient whose own HSCs have 
been destroyed by irradiation (or by chemotherapy for killing off the cancerous HSCs).  
The injected HSCs progress through the bloodstream and are able to recolonize the 
patient’s bone marrow, and produce more healthy blood cells that the patient lacked 
before.  The idea is to replace defective or non-existent blood cells with new progenitor 
cells that can produce healthy blood cells to replace the deficient ones (Hematopoietic 
Stem Cells, 2005).   Since an umbilical cord blood can easily be removed at birth (and is 
normally discarded), there is no need for a donor as long as the parents of the child decide 
to store the blood from the umbilical cord with a clinic that offers such a program.  The 
collection of the umbilical cord blood is simple and painless; it also has more primitive 
HSCs than bone marrow, making it more likely the donor will accept the transfused 
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blood.  The New York Blood Center’s Placental Blood Program, which is supported by 
the National Institutes of Health is the largest umbilical cord blood bank in the United 
States, and has over 13,000 donations available to those who need it (Hematopoietic 
Stem Cells, 2005).   In fact, umbilical cord blood HSC transplantations have become so 
successful, scientists are looking at them as an alternative to bone marrow transplantation 
(Gluckman, 2000).  The storing of umbilical cord blood for years until needed can seem 
expensive, however after factoring in the difficulty in finding a compatible donor for a 
bone marrow transplant, it can be a very wise choice, perhaps even life saving. 
 
HSCs for Treating Heart Disease 
 Promising (but not proven) applications have also been obtained using HSCs in 
the treatment of heart disease.  “Sixteen-year-old Dimitri Bonnville had been accidentally 
shot in the heart with a nail gun while doing home repair, undergone open-heart surgery 
and suffered a massive heart attack, when doctors told his parents he needed a heart 
transplant” (Philipkoski, 2003).  The doctors mentioned an alternative to a heart 
transplant; it had never been done before and was extremely new but showed promise.  
The doctors offered to perform an experimental stem-cell therapy that would inject 
Dimitri’s own HSCs directly into his heart.  The theory was that the stem cells ability to 
differentiate into any cell type would allow the stem cells to differentiate into the heart 
cells that were destroyed.  As the doctors described, 
“The teenager's therapy began Feb. 17 with a four-day regimen of a drug that stimulated 
the production of stem cells in his blood. On Feb. 21, doctors harvested Bonnville's stem 
cells. Using a heart catheter, they transplanted the stem cells into the artery that supplies 
blood to the front of the heart.  He was discharged about a week later and is now 
recuperating at home. His doctors say they have never seen a recovery like his 
(Philipkoski, 2003).” 
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The treatment worked perfectly, Dimitri’s stem cell therapy had saved him from having 
to obtain a heart transplant, and perhaps it even saved his life entirely.   
 Treatments such as this show that injecting specific adult stem cells into the 
damaged area is sometimes enough to instigate repair of the damaged area.  Research like 
this is becoming an important point for those against ES cell therapies, stating that ES 
cells would be totally unnecessary if sufficient adult stem cell types can be discovered.   
They also state that many lives have already been saved by adult stem cells, but that very 
few lives have been affected by ES cell research (Philipkoski, 2003). 
 
Adult Neuronal Stem Cell Applications 
 Umbilical cord blood and bone marrow aren’t the only adult stem cell treatments 
to show promise.  Significant advances with adult neural stem cells have also been 
achieved.  Michel Lévesque is a physician, neuroscientist, and neurosurgeon based at 
Cedars-Sinai Medical Center in Los Angeles.  He is also an Associate Clinical Professor 
of Neurosurgery at the UCLA School of Medicine, and member of the UCLA Brain 
Research Institute, the founder of NeuroGeneration, a biotechnology company pioneering 
autologous neural stem cell therapies, and Chairman of the Foundation for Neural Repair, 
a not-for-profit foundation, and sponsoring translational research to accelerate human 
trials using neural stem cells.  Dr. Lévesque testified to the Senate Committee on Science 
on the current usage and research of adult neural stem cells, as well as current and future 
research.  He stated that, “Since 1996, our laboratories have been involved with the 
isolation and characterization of human adult-derived neural stem cells, obtained from 
patients undergoing neurosurgical procedures.  In the adult brain, these cells cannot on 
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their own trigger repair responses. However, if placed in experimental laboratory 
conditions stimulating certain genes, these neural stem cells can be “awakened” and 
begin to divide and replicate events of normal development” (Levesque, 2005).  If neural 
stem cells could be coaxed into triggering a repair response, many degenerative brain 
diseases could potentially be cured by the neural stem cells in brain.  This is entirely 
possible because the human brain has the capacity to repair itself, but for some reason it 
lacks the means to activate the proper cells to do so.  Dr. Levesque has found a way to 
activate these adult neuronal stem cells into “turning themselves on” which could 
possibly lead to several treatments of brain disorders.  Levesque went on to say, “These 
newly created neural stem cells can grow for several months in laboratory conditions 
reaching several millions in number, a process called cell expansion. Their ability to self-
replicate and form all types of cells found in the central nervous system can be verified in 
vitro under controlled conditions. They can be placed in storage or maintained in sterile 
incubators until ready for use” (Levesque, 2005).  These new cells have been able to 
correct deficits in rat models of human Parkinson’s disease (Björklund et al, 2002).  The 
studies showed that, “human adult neural stem cells do not divide once differentiated, do 
not form aberrant tissue or tumors after chronic transplantation, and have normal 
karyotypes (number of chromosomes)” (Levesque, 2005).   
 Adult neuronal stem cell use is very promising for the treatment of degenerative 
diseases just like Parkinson’s in rat models, but the big question is can it be used to treat 
diseases in humans?  The answer is yes; “… [Dr. Lévesque] transplanted a patient with 
advanced Parkinson’s disease with differentiated neurons derived from an initial needle 
biopsy.  At three years post-operatively, the overall Unified Parkinson’s Disease Rating 
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Scale (UPDRS) improved by 81% while ‘on’ additional medication, and 83% while ‘off’ 
medication. We demonstrated here the long-term clinical remission of Parkinson’s 
disease symptoms in a single patient” (The Testimony, 2004). 
 Results like the ones Dr. Levesque obtained in his study are very promising for 
the treatment of degenerative brain diseases, as well as other non-neuronal diseases if the 
neuronal stem cells can be coached to trans-differentiate into other kinds of tissues.  Dr. 
Levesque believes that, “The current debate between the ES cell proponents and those 
who are opposed to their use distracts from other avenues with promising outcome, such 
as adult stem cell therapy,” (Levesque, 2005).  But he does believe in the potential of all 
stem cell research, including ES cells (Levesque, 2005).  The aforementioned research is 
about to enter Phase II clinical trials with the Food and Drug Administration. 
 
ES Cell Therapy 
 Although adult stem cells have the ability to differentiate into one or several cell 
types, and have fewer ethical concerns than embryonic stem (ES) cells, they don’t have 
the ability to differentiate into all cell types, and that is where ES cells get their “power”.  
Scientists hope to be able to be able to control ES cells in hopes of harnessing their 
pluripotency ability.   
“Stem cells have been widely touted as eventual cures for neurodegenerative diseases 
such as ALS and Parkinson's. The conventional wisdom is that they would be grown to 
produce the particular nerve cells that are lost in each disease, which would then be 
grafted into the nervous system to repair it. But researchers currently understand little 
about the signals that make stem cells differentiate into particular cell types, nor are they 
sure how to get grafted cells to integrate effectively into tissues and organs (Zandonella, 
2005).”   
 
 Research involving animal models for ES cell therapies has shown promising 
results, and has brought the potential use of ES cells in humans even closer to a reality.  
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At the Washington University School of Medicine, scientists transplanted differentiated 
mouse ES cells in a rat nine days after a spinal cord injury.  Two to five weeks later, the 
rat was examined via histological analysis and the results showed that the ES cells 
transplanted into the animal not only survived but differentiated in astrocytes, 
oligodendrocytes, and neurons.  Also, further analysis showed that only the rats that were 
treated with the ES cells showed hind limb and weight support while the other rats who 
were also afflicted with the same injury, did not (McDonald, 1999).  Other animal models 
using ES cells have also shown potential.  Scientists injected mouse ES cells into rat 
models of Parkinson’s disease.  The ES cells that were injected differentiated into 
dopamine producing neurons which are in severely low numbers in Parkinson’s patients.  
The results encourage the use of ES cells in cell-replacement therapy for Parkinson's 
disease (Kim, 2002). 
 The pluripotency of ES cells makes them difficult to work with however.  Since 
ES cells can differentiate into any cell type, controlling them can be a challenge.  
Neuroscientist Clive Svendson said that, “‘You have to learn to control that power in the 
dish’ before thinking about putting the cells into patients … For that reason, most groups 
say they are at least five or, more likely, 10 years away from ES cell clinical trials” 
(Vogel, 2005).  A company by the name of Geron (Figure 8) is attempting to significantly 
shorten that timeline.  It hopes to put therapies using ES cells into clinical trials as early 
as possible (Geron, 2004).  It is currently talking with the FDA to set up guidelines for 
the therapies.  But even advocates of ES cell research are skeptical about this.  They don’t 
want an already unstable and controversial field to have a failed clinical trial and lose the 
little support they have now.   
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Figure-8: Geron’s Possible Treatments Using ES Cells (Geron, 2004) 
 
 Geron is pushing ahead ever hopeful that their treatment to treat spinal cord 
injuries will be a complete success (Vogel, 2005).  Geron has “developed a protocol that 
encourages hES cells to differentiate into cells called oligodendrocyte precursors. These 
cells can form oligodendrocytes, the cells that, among other functions, produce the 
protective myelin sheath that allows neurons to send signals along their axons. This 
sheath is often lost during spinal cord injuries” (Vogel, 2005).  Geron’s treatment as 
previously described, would involve directly injecting human ES cells into a damaged 
spinal cord, the stem cells would then differentiate into the proper cell lines necessary to 
repair and maintain a healthy spinal cord.  Geron’s research showed tremendous results in 
their animal models tested last year.  Geron reported that, 
“For newly injured rats, the results are promising. In animals that received 
oligodendrocyte precursors 7 days after their injury, the cells survived and apparently 
helped repair the spinal cord's myelin. Within 2 weeks, treated rats scored significantly 
better on standardized movement tests than control animals, which had received human 
fibroblasts or a cell-free injection.  But when the researchers injected cells 10 months 
after the injury, they saw no effect--sobering news for people like Langevin suffering 
from old injuries. The cells survived but were apparently unable to repair the long-term 
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damage. For that reason, Keirstead says, Geron's proposed clinical trial would target 
newly injured patients” (Vogel, 2005). 
 
 
Providing this treatment safely will be a challenge however.  In some of the earlier trials, 
ES derived cells would sometimes differentiate into the wrong cell type, or would 
sometimes migrate away from the injection site.  “In its spinal cord trial, Geron plans to 
inject ES-derived cells that can form just a single cell type, an approach that may 
circumvent some of these problems.  For a full recovery, patients are likely to need new 
neurons as well as other support cells called astrocytes, but using precursors that 
differentiate into all three types of nerve cells can be problematic” (Vogel, 2005).  
Another and very serious problem may be the accidental creation of tumors.   
“One of the defining characteristics of ES cells is that they form disorganized tumors, 
called teratomas, when injected in undifferentiated form under the skin of immuno-
compromised mice. ‘The ES cell is basically a tumor-forming cell,’ says neuroscientist 
Anders Bjorklund of Lund University in Sweden. ‘This aspect has to be dealt with 
seriously before the cells are applied in the clinic.’ Even a benign tumor in the central 
nervous system would be serious, says Svendsen: ‘Any sort of growth in the spinal cord 
is not good news’” (Vogel, 2005). 
 
 
Geron scientists have stated that they have several protective measures in place to prevent 
this from happening in the clinical trials; however they do state that the procedure is still 
being worked on for improvements.  Despite the issues brought up by other scientists 
such as contamination issues, and avoiding more research being the first company to 
perform this type of therapy, Geron’s research shows promising results, and they are 
hopeful that even if their research doesn’t work the first time it will set standards for 
research in the future so companies that want to start this research won’t have to start 
from square one (Vogel, 2005). 
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Stem Cell Applications as Support Therapy 
 Other researchers believe that stem cells have even more potential than they’re 
currently being used for.  Evan Snyder, who works at the Burnham Institute in La Jolla, 
California stated that, “… cell replacement is an exciting future prospect. But apart from 
replacing lost cells, he notes that stem cells have other, more subtle roles that could be 
exploited therapeutically. Snyder has evidence that, in the nervous system, stem cells can 
act as 'chaperones' that nurse sick and injured neurons back to health” (Zandonella, 
2005).  Neural stem cells can secrete biochemicals that improved the function of neurons, 
as well as promote survival, decrease inflammation, and encourage the growth of blood 
vessels.  Research has shown that neural stem cells taken from rats secrete glial cell line-
derived neurotrophic factor (GDNF) which protects the cells and aids in the recovery of 
symptoms from Parkinson’s disease.  Snyder argues that, “You are not trying to replace 
the lost cells … instead, you are trying to protect what is there” (Zandonella, 2005).  
Using this therapy, researchers plan to take this approach to the FDA in hopes of treating 
Amyotrophic Lateral Sclerosis (ALS), which is better known as Lou Gehrig's disease 
(Zandonella, 2005).   
 
Chapter Conclusions 
 Stem cell research shows great promise in both the adult and embryonic fields.  
Both areas have medical treatments currently in or on the verge of clinical trials, and they 
both have great results from animal testing in the labs.  Despite the advances and promise 
of treatments, annual investments have dropped over the past couple years (Glaser, 
2004).  This is probably due to the constant debate over the ethical and moral status of ES 
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cells.  Unfortunately, sometimes all stem cell research gets incorrectly pulled into the 
debate of whether embryos should be destroyed for research, when this topic only 
pertains to ES cell research and not adult stem cells.  It is imperative to remember that 
adult stem cell research and therapies use the person’s own stem cells for treatment and 
don’t involve any “killing” of embryos.  With stem cell research being on the cusp of 
making life saving discoveries, it is even more important now than ever to try to 
understand all sides of the ethical and moral debate (to be discussed in Chapter 3). We 
need to work together as scientists and as a community to come to a mutual agreement on 
the status of embryonic and adult stem cell research so that the experts in this field can 
delve ever deeper into unlocking the mechanisms to control and utilize stem cells to their 
full potential. 
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CHAPTER-3:  STEM CELL ETHICS 
 
 
Now that the world has started to have the knowledge, ability and skill to use stem 
cells, an important question is, should we?   In September of 2005 a Gallup poll of 1,002 
adults nationwide, as seen in Table-I on the next page, asked people’s opinion about the 
origins of human life, how much this opinion affects their life, and whether their religious 
and scientific beliefs conflict (CNN, 2005).  It shows that 84% of people believe that God 
had at least some role in the evolution of humans, and 76% of people have thought about 
the origins of man at least a moderate amount (CNN, 2005).  Though this only illustrates 
the idealism of a monotheistic, or the belief in a singular entity, religion like Christianity 
or Judaism, this poll shows that the United States could be even more divided on whether 
humans should interfere with the “natural process of life,” especially when 66% of the 
people polled believe that their theological beliefs about creation mean a great deal or 
moderate amount to them (CNN, 2005).  There are some religions that believe that stem 
cell usage is murder and that scientists are playing god (Ayon, 2002).  What makes this 
question even more complicated is due to the different types and levels of stem cells, as 
discussed in Chapter 1 and 2, and how their religious beliefs could conflict with only 
some or all of the levels of stem cell use.  As the poll shows, 35% of people find that their 
religious and scientific beliefs conflict with each other (CNN, 2005).  Almost all religions 
may be accepting of adult stem cells, but some believe that the use of embryonic stem 
cells is sacrilegious.  As it can be imagined, religious controversy about stem cells is a 
major obstacle for the continuation of its research.  For this reason stem cell ethics is a 
worthwhile discussion. 
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Table I: CNN/USA Today/Gallup Poll. Sept. 8-11, 2005.  
N=1,005 adults nationwide. MoE ± 3 (CNN, 2005) 
 
 
Christianity and Stem Cells 
 
The first religious stance that should be looked at is Christianity.  The world’s 
largest religion, they have the most conservative and restrictive views on stem cell 
research.  When speaking about embryonic stem cell research, Archbishop Francis E. 
George stated that "history has shown that it is always the dispossessed, those whose 
lives are easily overlooked, who are subjected to the worst abuses of scientific research,'' 
and that the "so-called 'spare' human embryos are particularly vulnerable to this kind of 
moral blindness because so many people seem to have difficulty identifying with their 
humanity'' (US Bishops, 2006).  Christians believe that life begins at fertilization, which 
is when the egg and sperm combine and create a new genotype.  Biologically speaking, 
this is believed to be the beginning of a new human life (Shannon, 2006).  Professor 
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Thomas Shannon goes on to explain that “together with this affirmation is the correlative 
presumption that this is the time of the infusion of the soul. Although there is no official 
doctrine on this position, the attitude of the Church is that moral priority should be given 
to this position” (Shannon, 2006).  The Church believes that no matter how insignificant 
in size it may be, it is still life says Bishop Donald Wuerl, " while (a stem cell) is a tiny 
speck, it nonetheless contains the elements out of which comes the fully developed 
human person'' (US Bishops, 2006).   
Pope John Paul’s II address to the diplomatic corps on January 10, 2005 seems to 
exemplify the catholic position: 
“Conflicting views have been put forward regarding abortion, assisted procreation, the 
use of human embryonic stem cells for scientific research, and cloning. The Church's 
position, supported by reason and science, is clear: the human embryo is a subject 
identical to the human being which will be born at the term of its development. 
Consequently whatever violates the integrity and the dignity of the embryo is ethically 
inadmissible. Similarly, any form of scientific research which treats the embryo merely as 
a laboratory specimen is unworthy of man.” (Pope, 2005) 
 
The Pope goes on to explain that the “Scientific research in the field of genetics needs to 
be encouraged and promoted, but, like every other human activity, it can never be exempt 
from moral imperatives; research using adult stem cells, moreover, offers the promise of 
considerable success” (Pope, 2005).   
With this being said, there are a few within the Christian and Catholic Church that 
support embryonic stem cell research, arguing that the embryo is the potential for life but 
does not yet have the moral status of a born child.  This stance argues embryos should not 
be bought or sold (Farley, 2000), but can be used to save lives.  Doctor Ronald Cole-
Turner of the Pittsburg Theological Seminary and a member of the Protestant 
denomination, the United Church of Christ, explains that the majority of the members 
believe “that embryos have an important but less status” (Cole-Turner, 2000).  The 
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General Synod, the church-wide counseling body which is the voice of the church on 
particular issues, released a statement that the “human pre-embryo” should be treated 
with the utmost respect but that it has only the “potential to develop into full human 
personhood” and thus supports “human pre-embryo research, including research that 
produces and studies cloned human pre-embryos through the 14th day of fetal 
development.”  Human blastocysts from which ES cells are obtained are usually day-5.  
The only limitations were that the embryos are treated respectfully, they are not 
implanted, and that there is public discussion of current and future research (Cole-Turner, 
2000).  Thus, the Christian faith seems to be divided slightly on their views about 
embryonic stem cell research, but the majority believes it to be immoral.  They only all 
support the usage of adult stem cells as a community. 
 
Judaism and Stem Cells 
A more liberal ethical stand on stem cell research is that of Judaism.  A main 
theological certainty is that they accept “both natural and artificial means for overcoming 
illness” and that doctors are both “the agents and partners of God in the ongoing act of 
healing” (Dorff, 2000).  It is Jewish belief that they “have a duty to God to develop and 
use any therapies that can aid us in taking care of our bodies, which ultimately belong to 
God” (Dorff, 2000).  The second major controversy about stem cell research is when life 
begins.  Rabbi Yehiel Ben Ayon confirmed that “Judaism teaches that life begins at birth; 
hence the possibility to kill life can only begin at the same time as that life begins (Ayon, 
2002).  In Judaism, an unborn child is not life but the potential of life.  Certainly an 
unborn child may not be aborted, but to do so is not killing.  It is wrong.  It is forbidden, 
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but it is not killing.” (Ayon, 2002).  Dr. Rabbi Elliot N. Dorff, of the University of 
Judaism, explains that “Genetic materials outside the uterus have no legal status in Jewish 
law, for they are not even a part of a human being until implanted in a woman’s womb, 
and even then, during the first 40 days of gestation, their status is ‘as if they were simply 
water’” (Dorff, 2000).  Therefore, Jewish law and religious beliefs allow for embryonic 
stem cell research.  They also believe that the use of adult stems “is always accepted and 
even welcomed” (Ayon, 2002).  Rabbi Yehiel Ben Ayon continues that “Judaism does 
not see the artificial growth of human cells on a laboratory dish as a human life” and that 
“it is routine in medicine today to grow human skin for use in skin grafts.  Growing stem 
cells should then be seen in the same light” (Ayon, 2002).  These quotes show that 
followers of Judaism believe that embryonic and adult stem cell research is moral and 
should be encouraged as long as it is done for the common good.   
 
Buddhism and Stem Cells 
Buddhism is quite unlike the religions already spoken about because of one main 
fact; Buddhism is polytheistic, meaning that they believe in many gods.  Christianity and 
Judaism are monotheistic where they believe in one godly creator.  Buddhism does not 
believe in a “divine creator, whose plan might be distorted by human tinkering with 
nature” (Frazzetto, 2004).  They follow the teachings of the Buddha Śākyamuni.  
Buddhist ethics are not followed because it is law instead the Buddhist philosophy that is 
“designed as expressions of indisputable human rights or as a consequence of dignity 
inherent in every human being. Ethics are much more a matter of personal choice; 
principles like the one of ‘non-harming’ should be followed as guidelines” (Schlieter, 
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2004).  Therefore, there are many interpretations of when life begins and what the 
consequences are to your karma.  Karma is believed to be a sum of all of your actions in 
your current, past and future lives.  Therefore, how you act in one life will affect your 
reincarnation, or rebirth. 
Damien Keown, who is known as an expert on Buddhist biomedical issues 
explains that “Buddhism teaches that life may come into being in a variety of ways, of 
which sexual reproduction is but one, so sexual reproduction has no divinely sanctioned 
priority over other modes of procreation” (Frazzetto, 2004).  Buddhist teachings about 
embryology assume “that the transmigration of consciousness is sudden rather than 
gradual” (Hughes and Keown, 1995).  However, an article by James Hughes, from the 
MacLean Center for Clinical Medical Ethics and by Damien Keown, of the University of 
London, explains that there are a variety of views of when Buddhist believe ensoulment 
occurs: 
“Based on the findings of modern neuro-embryology Buddhists today might maintain 
that the fetus does not fully embody all five skandhas and the illusion of personhood until 
after birth; this is the argument developed by most Western ethicists to defend abortion.  
If the fetus is not yet a fully embodied person, then the karmic consequences of abortion 
would be even less than the killing of animals, which Buddhism teaches do have moral 
status. This neurological interpretation of the skandhas may be more consistent with 
Western Buddhism, which often sees the doctrine of rebirth as peripheral or interprets 
rebirth metaphorically rather than literally” (Hughes and Keown, 1995). 
 
Consequently, the actual definition of when life begins is not an exact time.  Therefore 
there are two main interpretations about this in Buddhist teachings.  A small segment of 
Buddhists believes that incarnation or conception “does not occur until as late as the 
seventh month.”  Though there is another larger segment that believes the 
“transmigration of consciousness occurs at conception, and therefore that all abortion 
incurs the karmic burden of killing” (Hughes and Keown, 1995).  Though abortion occurs 
later in the development of the fetus, it could be inferred that this segment of the 
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Buddhist would believe that stem cell research would have the same moral effects as 
abortion because the status of the fetus is the same at any point of its development.  
Though this might seem a reasonable rationale, it is still not so clear what Buddhism’s 
view on stem cells is.  Buddhism “encourages placing a strong value on respecting every 
living being, which includes fertilized embryos that are used for, or originate in, research 
activities” (Frazzetto, 2004).  Though, Yong Moon, a gynecologist at the University of 
Seoul and the lead author of the South Korean cloning paper, explains that “cloning is a 
different way of thinking about the recycling of life.  It's a Buddhist way of thinking” 
(Frazzetto, 2004).  This goes to show that stem cell research and usage would be just the 
continuation of life in a different way and thus would be supported.  Alternatively, 
Keown disagreed with Moons’ comments because “therapeutic cloning involves 
experimentation on immature human beings, it might be thought clearly contrary to 
Buddhist ethics” (Frazzetto, 2004).  This illustrates that there really is no one Buddhist 
opinion about embryonic stem cell research.  Conversely, adult cell research is approved 
by the Buddhist community explains Robert Hood, a practicing Buddhist and an editor of 
the Journal of Buddhist Ethics (Holmes, 2004). 
 
Islam and Stem Cells 
Similar to that of Buddhism, Islamic beliefs are based on textual information, 
mainly the Qur'an, without a major religious institution to guide the opinions of the 
followers.  Instead the Shari'ah, or the religious law of Muslims, is open to interpretation 
(Sachedina, 2000; Frazzetto, 2004).  There are two schools of thought, the Sunni and the 
Shi`ite.  The Sunni make up the majority of the Islamic followers and interpret the text in 
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a more traditional way than the Shi`ite (Sachedina, 2000).  Both sects do believe that they 
have an obligation serve society by using the knowledge that was given by God to help 
the common good (Frazzetto, 2004).  There many ideas about when the embryo reaches 
the moral status.  A majority of Muslims believe that ensoulment occurs 120 days after 
conception (Frazzetto, 2004).  The Shari'ah go further to make “a distinction between 
actual and potential life, determining that the former should be afforded more protection 
than the latter. Under most interpretations, the embryo is therefore not considered to be a 
person, and using it to create stem-cell lines would not violate Islamic law” (Frazzetto, 
2004).  Hassan Hathout, of the Islamic Organization for Medical Sciences in Kuwait, is 
quoted by Bill Broadway saying that “Islam opposes creating embryos with the intention 
of using them for research” (Broadway, 2001).  However, Dr. Abdulaziz Sachedina of the 
University of Virginia explains that “it is correct to suggest that a majority of the Sunni 
and Shi`ite jurists will have little problem in endorsing ethically regulated research on the 
stem cells that promises potential therapeutic value, provided that the expected 
therapeutic benefits are not simply speculative” (Sachedina, 2000).  It would be right to 
presume that both Islamic sects would support the use of adult stem cells since no life is 
destroyed in the process of cultivating them. 
There is also some Muslim disagreement over who could use the stem cells.  This 
is due to the fact that there is a great emphasis “on inter-human and familial 
relationships” (Frazzetto, 2004).  Giovanni Frazzetto explains that “the preservation of 
the parent−child lineage is of utmost importance to Muslims, as are the spousal 
relationships that encourage parental love and concern for their children.  Dr. Abdulaziz 
Sachedina explains further that “[The] Muslim focus of the debate on genetic replication 
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and embryonic manipulation is concerned with moral issues related to the possibility, 
through these technologies, of creating incidental relationships between a man and a 
woman without a spiritual and moral connection between them” (Frazzetto, 2004).  
Consquently, Islamic law prohibits surrogate parenting and adoption, but would allow 
“the adoption of human embryos,” when excess embryos exist, for research purposes as 
long as they are used only by the couple who created them (Frazzetto, 2004).   
 
Parthenote Ethics 
A relatively new way to obtain embryonic stem cells is through ‘parthenogenesis.’  
This process is also known as ‘virgin birth’ because chromosomes from the female egg 
are used without any fertilization from the male sperm.  “Scientists instead deceive the 
female egg cell into believing fertilization has taken place.  Using the chromosomes 
already present within the egg cell, cell division and embryonic development begins” 
(Cloning, 2006).  This process is very controversial due to the fact that there is no 
consensus if this “half-embryo” is considered life.  In an article by the Family Research 
Council it was stated that “scientists…destroy the embryos for their stem cells, discarding 
human dignity to satisfy scientific curiosity (Cloning, 2006).  As it can be seen there is 
already quite a bit of debate about parthenogenesis.  However, because the topic of 
human embryo parthenogenesis is so recent, thus far there has not been much written 
from the religions that were previously mentioned.  Instead the ethical and moral status of 
“embryos” created by parthenogenesis will be discussed by the opponents and proponents 
of the research. 
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Proponents of parthenotes believe that this process is a way to save fertilized 
embryos from destruction.  Guido de Wert and Christine Mummery continue to explain 
that: 
“As the parthenote undergoes the first divisions normally and is at these stages not 
distinguishable from embryos derived by normal fertilization, we would argue that it 
should be regarded as a non-viable embryo. In the light of its non-viability, the 
potentiality argument is not applicable. The moral status of parthenotes may therefore be 
regarded as very low, lower even than that of normal viable embryos at the same stage 
(see earlier). Thus, although not an ‘embryo-saving alternative’, all other things being 
equal, parthenogenesis may be regarded as ethically preferable to the generation of viable 
embryos by fertilization or nuclear transfer (for instrumental use)” (de Wert and 
Mummery, 2003). 
 
Proponents also believe that parthenotes are not living beings because “the embryo is 
unable complete gestation due to genetic components absent in the parthenogenesis 
process” (Cloning, 2006). 
However, Dr. William Cheshire retorts that “careful examination of all the 
medical evidence, however, fails to demonstrate conclusively that the living human 
parthenote cannot be a human being”, and that labeling a parthenote as “ambiguous 
humanity” does not justify its exploitation (Cloning, 2006).  Opponents believe that “the 
individual developing parthenogenetically would be genetically distinct from its mother” 
either by only having half of the mothers genetic code would make it an individual, or 
that through “normal development…the shuffling of genes will have produced 
peculiarities in the makeup of the offspring that altogether distinguish it from its mother 
(Latkovic, 2006).  Thus, these embryos would have the same moral status as any human 
being.  Though no successful human parthenote implantation has been attempted, the 
question as to whether this chemically modified embryo could successfully be implanted 
and thus be a distinct human being is unknown.  The only Catholic religious relationship 
to parthenogenesis mentioned was that because Christ was believed to be born though a 
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“virgin birth,” there are many Catholics that believe that embryos created though 
parthenogenesis have an even greater ethical status than embryos used from IFV clinics 
(Weiss, 2001).  
As seen by the many quotes of prominent religious figures and scholarly writers, 
the ethical and moral considerations of to stem cell use and policy are decidedly complex.  
There is not only a division of opinion about using embryonic stem cells and parthenotes 
between religions, but also between the members of the same religion.  As Dr. Cheshire 
explains, “...how society decides to treat the least of human lives is a measure of how it 
chooses to value vulnerable and impaired human beings in general” (Cloning, 2006).  
There will never be a national consensus on the ethical or moral status and rights of 
embryos used in embryonic and adult stem cell research, but it is imperative for the 
continuation and progress of stem cell research that we understand and respect these 
beliefs. 
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CHAPTER-4:  STEM CELL LEGISLATIONS 
 
 
 Ever since the successful creation of the first stem cell line by James Thompson in 
November of 1998, ethical and political turmoil engulfed the world and especially the 
United States (Weiss, 2005).  Now that the ethical controversy over embryonic and adult 
stem cell use has been discussed, it is understandable how difficult it is for a country or 
state to decide what their political or legislative regulations should be.  As figure-9 
illustrates below there are many “varied political climates” (Weiss, 2005).  The United 
Kingdom, China, Korea and Singapore (shown as dark orange with the permissive 
countries in the figure) have lenient regulations and have provided the most money 
towards stem cell research, while Germany (shown with the restricted countries in light 
yellow) has prohibited the research straight out.  United States stands in the middle.  The 
United States allows federal funding only on certain stem cell lines but allows the private 
sector much more freedom (Weiss, 2005).   
 
Figure-9: World Stem Cell Map (Check, 2005) 
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Stem Cell Policies Around the World 
 
 One organization that discusses issues of international law is the United Nations 
General Assembly (UNGA), which is a subset of the United Nations (UN) and is the only 
section of the UN in which all members are represented  (United Nations, 2006).  On 
March 8, 2005 the UNGA “approved a nonbinding resolution urging member states to 
adopt legislation ‘to prohibit all forms of human cloning in as much as they are 
incompatible with human dignity and the protection of human life’” (Johnson and 
Williams, 2006).  This announcement led the European Union (EU) to clarify their own 
regulations and rules to still continue to fund embryonic research (Johnson and Williams, 
2006).  Other EU nations have gone further to limit the research (Germany), or prohibit 
the research (Austria, Ireland, or Lithuania), while others have no regulations, Czech 
Republic or Portugal (Johnson and Williams, 2006).  Non-EU countries are just as 
diverse in their regulations; China, Japan and Columbia being the most liberal, and 
Ecuador being the most conservative.   
From August 9, 2001 to May 23, 2004, 128 human embryonic stem cell lines had 
been created.  A survey conducted by the Boston Globe also found that the majority of 
these were not created in the United States.  Specifically “94 were created in labs outside 
the United States, and 34 (26%) were created in this country” (Johnson and Williams, 
2006).  However by July 2005 (Figure-10), 70 ES cell lines had been created in the U.S. 
constituting 45% of 155 worldwide (Weiss, 2005).   
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Figure-10: ES Stem Cell Lines as of July 2005 (Weiss, 2005) 
 
Although 9 countries currently have ES cell lines, this does not mean that all countries 
necessarily have access to them for performing research; many countries have laws that 
limit or ban the distribution of stem cell lines created in their country.   For example, 
stem cell lines cannot be shipped abroad from the United Kingdom until the UK Stem 
Cell Bank has processed them (Johnson, 2006).  The United Kingdom’s Stem Cell bank 
is relatively new and was the first of its kind.  Glyn Stacey, the director of the bank, 
explains that it was created by the UK as a way to “apply the same rigorous standards to 
all cells” (Weiss, 2005).  Japan has much stricter regulations on their stem cell lines; they 
cannot be shipped to any laboratories in other countries (Johnson and Williams, 2006).   
 
Stem Cell Policy in the United States 
 
 The United States has struggled with the ethical stand point of funding human 
embryo work ever “since the advent of in vitro fertilization, which produced the first 
‘test-tube’ baby in 1978” (Dunn, 2005).  The United States began making political and 
legal distinctions about stem cells in 1997 with the Dickey Amendment.  This 
amendment was introduced by Representative Jay Dickey and made it illegal to use 
federal funds for embryonic research (Johnson and Williams, 2006).  One of the major 
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political hurdles with stem cell research is should the government pay for it even though 
there are citizens of the country who may believe it unethical and do not want their tax 
dollars used for it.  This was the reason for the Dickey Amendment.   
 During the Clinton Administration, when the first human embryonic stem cells 
were first created, Congress and Clinton reinvestigated the (Johnson and Williams, 2006).  
In 1993, Congress and President Clinton enacted the National Institutes of Health 
Revitalization Act which gave the National Institute of Health (NIH) “direct authority to 
fund human embryo research for the first time” (Dunn, 2005).  The first step that the NIH 
took with this new power was to “establish a panel of scientists, ethicists, public policy 
experts, and patients' advocates to consider the moral and ethical issues involved, and to 
determine which types of experiments should be eligible for federal funding” (Dunn, 
2005).  By 1994, the panel, called the NIH Human Embryo Research Panel, presented 
their recommendations to the federal government.  They came to the conclusion “that the 
destruction of spare embryos from fertility clinics, with the goal of obtaining stem cells, 
should receive federal funding” (Dunn, 2005).  President Clinton took into consideration 
all of the NIH’s recommendations but believed that the NIH should “not to allocate funds 
to experiments that would create new embryos specifically for research” (Dunn, 2005).  
However, the Congress did not agree with President Clinton.  In 1995 the Congress 
attached the Dickey-Wicker Amendment to the appropriations bill for the Department of 
Health and Human Services that “banned the use of federal funds for any experiment in 
which a human embryo is either created or destroyed” (Dunn, 2005).   
 The next milestone for both the political and scientific community was in 1998.  
James Thomson, of the University of Wisconsin, “successfully created the first human 
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embryonic stem cell lines” (Thomson et al., 1998; Dunn, 2005).  Harold Varmus, director 
of the NIH, explained that “this [embryonic stem cell] research has the potential to 
revolutionize the practice of medicine” (Dunn, 2005).  Finally, in 1999, the Dickey-
Wicker Amendment which had been limiting all embryonic stem cell research to only 
private funding was overruled by Harriet Rabb, the head lawyer at the Department of 
Health and Human Services.  Her legal opinion was that human embryonic stem cells 
“are not a human embryo within the statutory definition," and therefore the Dickey-
Wicker Amendment would not apply to them (Dunn, 2005).  This conclusion allowed the 
NIH to allow federal funding for the research.  By 2000 the NIH and the Clinton 
Administration created strict guidelines about the type of cell that would be given the 
funding (Dunn, 2005).  The NIH guidelines also prohibit: 
“(1) research in which human stem cells are utilized to create or contribute to a human 
embryo; (2) research in which human stem cells are combined with an animal embryo; 
(3) research in which human stem cells are used for reproductive cloning of a human; 
(4) research in which human stem cells are derived using somatic cell nuclear transfer, 
i.e., the transfer of a human somatic cell nucleus into a human or animal egg; (5) 
research utilizing human stem cells that were derived using somatic cell nuclear 
transfer; and (6) research utilizing stem cells that were derived from human embryos 
created for research purposes, rather than for infertility treatment” (Johnson and 
Williams, 2006). 
 
The Dickey-Wicker Amendment still applied though to one aspect of the research; no 
embryos could be destroyed in the process of creating the stem cells (Dunn, 2005). 
 Unfortunately by 2001, President Bush took over office before any of the grant 
applications submitted to the NIH for federal funding were approved.  The Bush 
Administration reviewed all the policies that Clinton had created, and asked the NIH to 
prepare a “scientific review…of the status of the research and its applications” (Johnson 
and Williams, 2006).  The NIH report supported the continuation of both embryonic and 
adult stem cell research, but did not make any direct recommendations to the Bush 
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Administration (Johnson and Williams, 2006).  On August 9, 2001, Bush went and undid 
everything that President Clinton had done to expand and encourage embryonic stem cell 
research when he “announced that federal funding would now be restricted to a limited 
number of stem cell lines already created by that date” (Dunn, 2005).  President Bush 
explained that his decision “allows us to explore the promise and potential of stem cell 
research without crossing a fundamental moral line, by providing taxpayer funding that 
would sanction or encourage further destruction of human embryos that have at least the 
potential for life” (Johnson and Williams, 2006).  Under Bush’s regulations federal funds 
could “only be used for research on existing stem cell lines that were derived (1) with the 
informed consent of the donors; (2) from excess embryos created solely for reproductive 
purposes; and (3) without any financial inducements to the donors”, and could “not be 
used for (1) the derivation or use of stem cell lines derived from newly destroyed 
embryos; (2) the creation of any human embryos for research purposes; or (3) the cloning 
of human embryos for any purpose” (Johnson and Williams, 2006).  On a positive note, 
the Bush Administration would support the continuation of stem cells “which do not 
involve the same moral dilemma,” as in those from umbilical cord blood, placentas, and 
adult and animal tissues (Johnson and Williams, 2006). 
Unfortunately, of the 78 legally approved ES cell lines that are approved for U.S. 
funding, only 22 are actually suitable for the research (Figure 11).   
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Figure-11: Stem Cell Lines (Weiss, 2005) 
 
Many scientists believe that this restriction on stem cell lines will keep the United 
States from being at the forefront of the research.  As quoted in figure-11, Douglas 
Melton of Harvard University says that many of the currently approved ES cell lines have 
lost the potential to differentitate due to poor culture conditions.  Stephen Minger is the 
director of the Stem Cell Biology Laboratory at King’s College in London and feels that 
“the United States is in real danger of being left behind” because of the “political 
uncertainties in the United States (Weiss, 2005).  Another problem with the Bush policy 
is the viability of the current stem cell lines that are approved for funding.  All of them 
were developed using new techniques that created lines that are “harder to work with, not 
well characterized, and genetically unstable” (Johnson and Williams, 2006).  For this 
reason, in 2004, over 200 Members of the House of Representatives wrote a letter to 
Bush asking him to change his current policy so to make use of the extra embryos created 
during IVF.  Their largest concern was the stem cell line limitation that Bush set would 
keep the “research from being successful…[as US scientists] move to countries like the 
United Kingdom, which have more supportive policies” (Johnson and Williams, 2006).   
The NIH director sent a response that hinted that the research could do better with more 
stem cell lines, but Bush’s ethical reservations prevent him from loosening the 
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restrictions (Johnson and Williams, 2006).  Some progress was made after the Senate did 
the same as the House of Representatives’.  The NIH would create new centers whose 
main objective is to find out how stem cells could treat many diseases, as well as create a 
National Embryonic Stem Cell Bank, similar to that of the UK, that would collect stem 
cell lines eligible for federal funding.  Unfortunately this progress was not progress at all 
to some.  The President of the Coalition for the Advancement of Medical Research 
explained that “creating a bank to house stem cell lines created before August 2001 does 
nothing to increase the wholly inadequate supply of stem cell lines for research” (Johnson 
and Williams, 2006). 
 Then, on May 20th, 2005 Bush made it quite clear that he would not loosen his 
embryonic stem cell policy: "I'm a strong supporter of adult stem cell research, of course.  
But I made it very clear to the Congress that the use of federal money, taxpayers' money, 
to promote science which destroys life in order to save life is -- I'm against that.  And 
therefore, if the bill does that, I will veto it” (Baker, 2005).  By July 19th, 2006 both the 
House and Senate had passed an embryonic stem cell bill that would lift restrictions on 
federally funded embryonic stem cell research (Klein, 2006).  But on July 20th the 
inevitable happened; Bush vetoed his first bill during his administration.  Bush believed 
that “if this bill were to become law…American taxpayers would for the first time in our 
history be compelled to fund the deliberate destruction of human embryos” (Babington, 
2006).  It is definitely clear that there will be no progress in the expansion of federally 
supported ES cell research.  However, almost 70% of the US population believes that the 
ethical problems that Bush sees in the research should not hold back the research (Figure-
12).   
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Figure-12: Public Support for Stem Cell Research Grows: Poll (Public, 2005) 
 
State Policies 
 
 Luckily state laws are able to sidestep both Bush’s regulations and the Dickey 
Amendment and help fund ES research with their own money.  State policy is just as 
varied as countries around the world (Figure-13).   
 
Figure-13: “Stem Cell Legislations in the U.S. by State” (Stem Cell Legislation, 2005). 
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California has led the way, promising 300 million dollars a year for the next decade on 
embryonic stem cell research (Wiess, 2005).  Many states hope that by encouraging the 
research they will stimulate their economies and create much needed jobs (Weiss, 2005).  
Other states, like Connecticut, Massachusetts and New Jersey are doing the same, making 
them advocates of stem cell research as well.   Here in New England, a Biomedical 
Research Advisory Council was created in Massachusetts through the enactment of 
Senate Bill 2039.  This bill was vetoed by Gov. Mitt Romney, but luckily the Senate 
overrode his veto (Massachusetts, 2005).  The council will “examine the appropriateness 
of public funding for research on stem cells from umbilical cord blood, and assess the 
feasibility of establishing an Institute for Regenerative Medicine at the University of 
Massachusetts Medical School” (State, 2006).  The bill also will make it easier for 
scientists to conduct stem cell research by removing a requirement to get approval from 
the local district attorney before starting, as well as giving the regulatory controls over to 
the Health Department (Massachusetts, 2005).  More recently, on July 31, 2006, 
Massachusetts is considering funding a life sciences center that would include stem cell 
research (State, 2006).  It is the hope that this new legislation will bring Massachusetts to 
the head of ES stem cell research.  
 
Chapter Conclusion 
 Hopefully with more states supporting the research and a new election year 
approaching, expansion of funding will help keep the United States at the forefront of the 
research.  Senator Edward M. Kennedy said it best: “There are some issues you just can’t 
get off the national agenda, and this is one…Stem cell research is going to happen.  It’ll 
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happen quicker with the President’s support, but all of us who are supporting this 
important research know that it is inevitable.  It’s just a question of when.” 
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CONCLUSIONS 
 
 
 Despite the numerous advances in both embryonic and adult stem cell research, 
both areas of stem cell research have had difficulties stemming from political and moral 
debates, lack of funding, and scientific hurdles that need to be crossed before major 
clinical advances can be accomplished. 
 We the authors feel that all stem cell research, including the research of 
embryonic stem cells and parthenotes, should proceed with few restrictions.  We believe 
the benefits that can be obtained through the use of stem cells in applied medical 
therapies and treatments, such as possible cures for Alzheimer’s and Parkinson’s, are too 
great to ignore.  In order for research to use embryos from IVF clinics, we believe that 
the parent of that embryo must consent to the donation of the embryo for research, and 
must be made fully aware of its use through written documentation. 
We also believe that government and private funding should be allowed to help 
aid the already challenged field.  We, the authors, believe that the current restrictions put 
in place by the US government in August 2001 are too strict and should be lifted to allow 
full federal funding for all stem cell research, including ES cells. 
 However, we do believe that some light restrictions are in order.  We believe the 
research and consequent therapies to follow should only be used for medical research for 
the purpose of trying to save human lives.  The use of stem cells for “cloning farms” or 
any other applications other than those in the medical field should be prohibited.  We also 
think a government agency, FDA or perhaps a new agency, should oversee all stem cell 
related therapies being introduced into the market to ensure a certain level of quality and 
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adherence to standards.  These standards would be set by that agency after a mutual 
consensus is reached by an expert panel on current stem cell research. 
 The medical promise of stem cell research is too great to be ignored, and unless 
we as a nation can come to a consensus on their use, the U.S. will fall behind other 
countries in stem cell research, and as such would fail to benefit from what many 
scientists argue is medicine for the new millennium. 
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